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Abstract: Atrial fibrillation is the most commonly seen arrhythmia in the geriatric population 
and is associated with increased cardiovascular morbidity and mortality. Treatment of the elderly 
with atrial fibrillation remains challenging for physicians, because this unique subpopulation 
is characterized by multiple comorbidities requiring chronic use of numerous medications, 
which can potentially lead to severe drug interactions. Furthermore, age-related changes in the 
cardiovascular system as well as other physiological changes result in altered drug pharmacoki-
netics. Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as 
atrial fibrillation and/or atrial flutter. Dronedarone is a benzofuran amiodarone analog which 
lacks the iodine moiety and contains a methane sulfonyl group that decreases its lipophilicity. 
These differences in chemical structure are responsible for making dronedarone less toxic 
than amiodarone which, in turn, results in fewer side effects. Adverse events for dronedarone 
include gastrointestinal side effects and rash. No dosage adjustments are required for patients 
with renal impairment. However, the use of dronedarone is contraindicated in the presence of 
severe hepatic dysfunction.
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Introduction
Atrial fibrillation is the most common arrhythmia requiring medical therapy, and 
increases in prevalence with advancing age.1 The long-term incidence of hospital-
ization related to atrial fibrillation is high, which makes prevention a key factor.2 
According to a study conducted by Go et al, atrial fibrillation is more common in 
men than in women, with an increase in prevalence in persons aged 80 years or older. 
They projected that this prevalence will increase to more than 5.6 million by the year 
2050, with more than 50% of affected individuals being aged 80 years or older.3 The 
presence of atrial fibrillation translates into significant morbidity and mortality for the 
patient. Stroke, thromboembolism, heart failure, impaired quality of life, and recur-
rent hospitalizations are frequently encountered complications in patients with atrial 
fibrillation.4 Of all these adverse events, stroke is by far the most feared, often leading 
to severe disability or even death.5 The Framingham study showed atrial fibrillation is 
an independent risk factor for stroke.6 It is estimated that atrial fibrillation is respon-
sible for over 60,000 strokes each year in the United States.7 Stroke is the second 
most common cause of death in the world. Almost 90% of deaths caused by stroke 
occur in people over 65 years of age.8 Consequently, contemporary therapy for atrial 
fibrillation has two major goals, ie, symptom relief and prevention of complications, 
including stroke and heart failure.
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Treatment of patients with atrial fibrillation poses a 
great challenge and can broadly be divided into two major 
therapeutic strategies, ie, rate control and rhythm control. 
Interestingly, two of the largest studies to date focusing on 
this topic, ie, the AFFIRM (Atrial Fibrillation Follow-up 
Investigation of Rhythm Management) and AF-CHF (Atrial 
Fibrillation in Congestive Heart Failure) trials, were both 
unable to show that antiarrhythmic drugs provided any 
reduction in stroke rate when compared with placebo.9 
A post hoc analysis of the AFFIRM data revealed that 
although maintenance of sinus rhythm was associated with 
better survival, this benefit was neutralized by increased 
mortality resulting from antiarrhythmic drug use.10 
A criticism that is often raised in regard to AFFIRM and 
AF-CHF is the fact that both trials were under-represented 
in regard to percentage of geriatric subjects enrolled. One 
would expect that precisely this age population is most at 
risk for developing arrhythmia. Other antiarrhythmic drugs, 
such as dofetilide and dronedarone, have been primarily 
studied in elderly patients. This could potentially give them 
a leading edge over the older drugs when prescribing for 
the geriatric population. The commonly prescribed dose of 
dronedarone (400 mg bid) has been extensively studied in 
a patient population with atrial fibrillation and of mean age 
72 years, in which more than 80% of subjects were older 
than 65 years.11
Physiological changes  
in the geriatric population
The myocardium experiences electrical and structural 
changes, such as increased fibrosis resulting in decreased 
ventricular compliance, as a direct consequence of aging. 
This loss of ventricular compliance translates into increased 
diastolic filling pressures, which in turn facilitate the devel-
opment of atrial fibrillation.12 The increased stiffness of the 
ventricular myocardium inhibits inflow and causes not only 
elevated filling pressures but also a progressive increase 
in atrial diameter. Electrophysiologically, in older age, the 
action potential duration and the effective refractory period 
of both atrial and ventricular tissue become longer, whereas 
conduction at the atrioventricular junction slows.13
In elderly people, the arrhythmia source is also changed 
by scarring resulting from myocardial infarction, ischemia, 
and increased stretch. Other possible etiologies include ven-
tricular, valvular, and systemic disorders (viral infections, 
systemic amyloidosis, ankylosing spondylitis) resulting in 
collagen, amyloid, and fibrosis formation, which ultimately 
contribute to generation of arrhythmia.
Pharmacokinetics, 
pharmacodynamics, and 
pharmacogenetics in the elderly
Limited data are available from clinical studies regarding 
the pharmacokinetics and pharmacodynamics of antiar-
rhythmic drugs in elderly subjects. Age-related changes in 
pharmacokinetics and pharmacodynamics make the elderly 
more prone to the development of adverse drug reactions, 
especially when incremental comorbidities are taken into 
account. Consequently, many elderly patients suffer from 
polypharmacy, making drug interactions more likely. The 
altered pharmacokinetics of aging change the effects of 
absorption, bioavailability, distribution, and clearance of 
drugs.
Absorption
The geriatric population has increased gastric pH,   secondary 
to atrophic changes in the gastric mucosa, with diminished 
acid secretion capacity and reduced gastrointestinal blood 
flow. Thus, elevated gastric pH is common in the elderly 
and can affect the ionization and solubility of certain drugs. 
Reduced acidity can also provoke more rapid emptying 
of the stomach contents into the duodenum. An age-
related decline in gastrointestinal motility has also been 
described.14
Bioavailability
Due to a decreased first-pass extraction, the bioavailability 
of some drugs with a high rate of first-pass metabolism may 
be increased.
Distribution
Changes in body composition can affect drug disposition. 
There is an age-related increase in body fat, decrease in 
lean body mass, and decrease in total body water. These 
alterations can result in an increased volume of distribu-
tion of lipid-soluble drugs and a diminished volume of 
distribution for water-soluble drugs. In the elderly, serum 
albumin levels may decline, with the total plasma protein 
content being unaffected. A reduction in albumin levels can 
result in an increase in the free drug fraction, which is the 
pharmacodynamically active part of the medication. α1 acid 
glycoprotein binds mostly to basic lipophilic drugs and this 
tends to increase with age. The binding of drugs to α1 acid 
glycoprotein also increases during an acute illness, such as 
myocardial infarction, and is a factor that needs to be taken 
into consideration by the prescribing physician.
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Hepatic metabolism
Several changes in liver structure and function have been 
noted in the elderly. There is an absolute decrease in the 
size of the liver and a reduction in hepatic blood flow. The 
most frequently seen changes involve the microsomal mixed-
function oxidative system (phase I, oxidation and reduction), 
with little or no change in conjugative processes (phase II, 
conjugation). Nevertheless, sometimes liver microsomal 
mono-oxygenase levels remain unaltered despite increasing 
age, perhaps due to interindividual variability. Another area 
of interest is hepatic enzyme induction in the elderly. There 
is still controversy as to whether drug induction is an impor-
tant phenomenon in the geriatric population. Cytochrome 
P450 (CYP) 2D6 inhibitors, such as quinidine, amiodarone, 
dronedarone, paroxetine, and propafenone, have been shown 
to diminish the metabolism of metoprolol, resulting in higher 
than expected plasma concentrations. Strong CYP3A4 inhibi-
tors, such as ketoconazole, are associated with a marked 
increase in maximum dronedarone concentration and are thus 
contraindicated, and inducers of CYP3A4 will conversely 
decrease dronedarone exposure. Some antiepileptic drugs, 
like carbamazepine and phenytoin, as well as certain antibi-
otics, such as rifampicin, induce metabolism by increasing 
the induction of CYP3A4. This leads to subtherapeutic and 
ineffective concentrations of quinidine, disopyramide, and 
dronedarone. Dronedarone is a substrate for P-glycoprotein 
and will lead to an increase in concentration of P-glycoprotein 
substrates, such as digoxin.15
Excretion
Glomerular filtration rate gradually declines with age. At the 
same time, there is a decrease in renal plasma flow, causing 
the filtration fraction to rise significantly with age. Loss of 
tubular function and diminished reabsorptive capacity are 
also observed with aging. Owing to reduced muscle mass, 
evaluation of renal function with serum creatinine alone 
can be misleading in elderly subjects.16 A more precise way 
to estimate glomerular filtration rate is by estimation of the 
endogenous creatinine clearance using the Cockcroft and 
Gault equation, which is a very useful tool for dose adjust-
ment of renally excreted drugs:
 
eCCr =
×
×
() 140
72
−× AgeM ass(inkilograms) [0.85if Female]
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When serum creatinine is measured in µmol/L:
 
eCCr =
×× () 140−AgeM ass(inkilograms) Constant
SerumCreatinine(in nm ol/L µ )
While the concomitant use of diuretics, nephrosclerosis 
due to hypertension, general anesthesia, and presence 
of congestive heart failure commonly encountered in 
elderly patients can lead to further renal compromise, age 
remains an independent risk factor for deterioration of 
renal function. In summary, all these factors that impair 
renal drug clearance can lead to drug accumulation and 
toxic effects.
Pharmacogenomics
The role of pharmacogenetics in daily clinical practice is 
increasing as practical guidelines regarding gene–drug 
interactions become more available.17 The aim of pharmaco-
genetics is to establish connections between pharmacology 
and genetics, in particular connections between pharma-
cological phenotypes and genotypes, to predict individual 
responses to drug treatments. The term pharmacogenetics 
is not recent, and was introduced in the early 1960s by 
Vogel,18 based on earlier studies of person-to-person vari-
ability in response to drug treatment.19 Since that time, 
several studies have shown that the CYP enzyme system 
is responsible for the metabolism of more than 80% of 
commercially available drugs.20 Therefore, interindividual 
differences seen in the response to treatment, as well as in 
the appearance of drug side effects, are caused by variations 
in CYP   encoding genes. Due to polypharmacy in the elderly 
population, adverse drug reactions are an important cause 
of morbidity and mortality.
Most currently prescribed drugs derive from natural 
plant metabolites, and are metabolized by enzymes encoded 
by CYP genes, which show a high rate of polymorphism.21 
Regarding the evolution of drug-metabolizing enzymes, the 
occurrence of a large number of duplications in CYP genes 
was documented about 300–400 million years ago.
The CYP enzymes encoded by CYP genes are part 
of a highly polymorphic gene superfamily, thus the high 
rate of polymorphism displayed by these genes leads to 
marked variability in the activity of the encoded enzymes. 
For this reason, CYP enzymes play an important role 
in drug metabolism, determining drug bioavailability, 
and therefore the clinical response to pharmacological 
treatments.
Clinicians should be aware of the implications when 
prescribing drugs to the elderly, and consider the current 
knowledge of pharmacogenetics in their clinical practice. 
Some investigators advocate that differences in the genetics 
of CYP will lead to personalized drug treatments, with a 
special emphasis on the geriatric population.
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Factors to consider in 
antiarrhythmic treatment  
for the elderly
Given that aging is associated with an increased risk of 
adverse effects, selection of antiarrhythmic drugs in the 
elderly is basically determined by factors such as the treatment 
target, assumed patient compliance, possible interaction with 
other medications the patient is concomitantly taking for 
comorbidities (eg, hypertension, congestive heart failure), 
and renal and liver function. Therefore, prescription of 
antiarrhythmic drugs in the elderly often involves dosage 
modification. As a general rule, a 50% reduction in the starting 
dose of an antiarrhythmic drug compared with younger 
patients would seem to be a wise approach. However, this 
does not apply to dronedarone (which has been specifically 
studied in an elderly population) or dofetilide.
Amiodarone: properties and side 
effect profile
Amiodarone is generally considered the gold standard in anti-
arrhythmic therapy and has the best efficacy in terms of main-
taining normal sinus rhythm in patients with atrial fibrillation.22 
Nevertheless, its use is often limited by its side effect profile. 
Potentially life-threatening proarrhythmic adverse drug reac-
tions have been described with amiodarone, such as torsades 
de pointes, but their incidence seems to be very low.23,24
The most common cardiovascular side effects include 
bradycardia, atrioventricular conduction abnormalities, and 
QT prolongation. First degree heart block and bradyarrhyth-
mia have been reported.25
However, in the setting of heart failure, amiodarone 
has been recommended because of its low proarrhythmic 
potential and lack of a significant negative inotropic effect 
in congestive heart failure.26 The presence of left ventricular 
systolic dysfunction does not significantly affect the outcome, 
indicating the utility of amiodarone for controlling atrial 
fibrillation in patients with congestive heart failure.
Dronedarone, a newer drug, has no proarrhythmic poten-
tial, and almost no incidence of torsades de pointes, with only 
one case in ATHENA (A placebo-controlled, double-blind, 
parallel arm Trial to assess the efficacy of dronedarone 400 mg 
twice daily for the prevention of cardiovascular Hospitalisation 
or death from any cause in patiENts with Atrial fibrillation/
atrial flutter). Data suggest that concomitant administration of 
dronedarone and digoxine results in an increase in maximal 
concentrations of digoxine.27 Thus, amiodarone has a rela-
tively safe cardiac adverse drug reaction profile.28
Pulmonary toxicity is a very common noncardiac side 
effect.29 The prevalence is estimated to be about 5%.30 
Although amiodarone-induced pulmonary toxicity can occur 
at any time after treatment is initiated, those considered at 
greatest risk are individuals who have received a daily dose of 
400 mg for more than 2 months, or a lower dose, commonly 
200 mg daily, for more than 2 years. In the earliest descrip-
tions of amiodarone, the reported incidence of amiodarone-
induced pulmonary toxicity was 5%–15% when patients were 
taking 400 mg or more per day.31 Subsequently, lower doses 
were used in an attempt to avoid toxicity. As emphasized by 
Polkey et al, there is probably no safe dose of this medication, 
and this complication continues to be reported.32
Hypersensitivity pneumonitis can appear early in the 
course of therapy. Interstitial pneumonitis is a more common 
but insidious pulmonary reaction characterized by cough, 
low-grade fever, and dyspnea that occurs after months or 
years of therapy.
The overall incidence of amiodarone-induced thyroid 
dysfunction is about 15%. The incidence of amiodarone-
induced hypothyroidism ranges from 1%–31%, and it is 
more frequent in iodine-sufficient areas. The presence of 
antibodies against thyroid peroxidase, an enzyme in thyroid 
hormone metabolism, is related to an increased risk of devel-
oping hypothyroidism during treatment with amiodarone 
(seven-fold in men and 13-fold in women). Therefore, it 
may be advisable to measure thyroid peroxidase antibodies 
at the start of amiodarone treatment. The reported incidence 
of amiodarone-induced thyrotoxicosis is in the range of 
1%–23%. Amiodarone-induced thyrotoxicosis develops in 
3% of amiodarone-treated patients in North America, and 
is classified as type 1 or type 2. Type 1 disease occurs in 
patients with underlying thyroid pathology, such as autono-
mous nodular goiter or Graves’ disease. Type 2 disease is 
a result of amiodarone causing a subacute thyroiditis with 
release of preformed thyroid hormones into the circulation.33 
Amiodarone also inhibits type 15′-deiodinase activity in 
peripheral tissue. Amiodarone and its metabolites demon-
strate direct toxicity in cultured thyroid cells exposed to 
media with concentrations above those normally found in 
patients.34 The effects of amiodarone on the thyroid can be 
seen as early as a few weeks after starting treatment and/or 
up to several months after its discontinuation.35
Because thyroid dysfunction is relatively common in 
amiodarone therapy, all patients should have free thyroxine 
and thyroid-stimulating hormone levels measured before 
starting therapy, at 3–4-month intervals during treatment, and 
for at least 1 year after amiodarone is discontinued.
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Optic neuritis or neuropathy, which causes patients to 
experience decreased or blurred vision, may progress in 
exceptionally rare cases to permanent blindness. Nearly all 
patients have microdeposits of amiodarone in the cornea, 
but this is rarely a reason to discontinue the drug.36 This is a 
dose-independent phenomenon and is reversible after cessa-
tion of the drug. Halo vision, especially in the dark, can be 
disturbing, and lowering of the dose is generally effective in 
the long term. Optic neuritis is very rare, and usually starts 
within 12 months of initiation of treatment, at a median of 
4 months. If optic neuritis develops, amiodarone must be 
discontinued.
Hepatotoxicity is a relatively uncommon side effect 
of amiodarone.37 Although asymptomatic elevation of 
aminotransferases is reported in up to 25% of patients, 
symptomatic hepatic dysfunction occurs in less than 1% 
of patients on chronic amiodarone therapy.38 Risk factors 
for developing hepatotoxicity are not defined. It may be 
difficult to prove the pathogenic role of amiodarone in a 
patient developing liver disease while on therapy with this 
drug.39 It is also not known whether patients with underly-
ing asymptomatic chronic liver disease are predisposed to 
amiodarone-induced hepatotoxicity. Clinically, amiodarone 
hepatotoxicity occurs in two settings, ie, with use of rapid 
intravenous infusion of amiodarone in the intensive care 
setting to control arrhythmias and with long-term oral use. 
The former usually presents as severe acute hepatitis with 
a massive rise in transaminases, occasionally leading to 
acute liver failure. Most cases recover after the infusion is 
discontinued. However, fatal instances of progressive liver 
failure have occurred. Although controversial, it is believed 
that this acute reaction is an effect of polysorbate 80, which 
is used to solubilize the intravenous preparation of amio-
darone, rather than the drug per se.40 This is consistent with 
the fact that oral amiodarone has been successfully used in 
patients who have developed acute hepatitis after intrave-
nous use of amiodarone.41 However, chronic amiodarone 
toxicity usually presents as mild asymptomatic elevation 
of liver enzymes. It is usually alanine aminotransferase 
and aspartate aminotransferase that are elevated to 2–10 
times the upper limit of normal.42 Other liver chemistries 
(alkaline phosphatase, gamma-glutamyl transferase, 
bilirubin, and lactate dehydrogenase have not been shown 
to vary significantly in patients on chronic amiodarone 
therapy. Aminotransferase elevation is usually reversible 
after dose reduction or drug discontinuation, although it 
may take anywhere between 3 weeks and 9 months for 
liver biochemistry to normalize. It is not known whether 
continued therapy in patients with mildly elevated liver 
enzymes leads to progressive and symptomatic hepatic 
dysfunction. Symptomatic liver disease develops in only 
1%–3% of patients. With prolonged treatment, amiodarone 
hepatotoxicity may insidiously progress to cirrhosis and 
present with signs and symptoms of decompensated liver 
failure, portal hypertension, and laboratory evidence of 
hypoprothrombinemia and hypoalbuminemia, although this 
is rare.43 A mean cumulative dose of 380 g was found in 
patients with hepatotoxicity leading to cirrhosis. Cirrhosis, 
although uncommon, has been well documented.44
Several types of dermatological reactions have been 
reported, including allergic rash, photosensitivity, and 
blue-gray skin discoloration.45 Neurological side effects are 
uncommon, and include tremor, ataxia, peripheral neuropa-
thy, malaise or fatigue, sleep disturbances, dizziness, and 
headaches.
In summary, amiodarone is a safe and efficacious antiar-
rhythmic agent when lower doses are used in patients who 
are closely monitored and subjected to careful follow-up. 
However, it is imperative that physicians are aware of these 
potentially severe drug-induced complications.
Dronedarone, a new antiarrhythmic 
drug
Dronedarone (Sanofi-Aventis, Bridgewater, NJ) is the first 
antiarrhythmic drug used in the treatment of atrial fibrillation 
and atrial flutter that has been shown to reduce cardiovascular 
hospitalizations.46 Dronedarone is also a potent coronary 
vasodilator in the hearts of rabbits, guinea pigs, and rats 
via nitric oxide synthase-mediated and guanylyl cyclase-
mediated effects.47
After oral administration, 70%–94% of dronedarone 
is absorbed in the postprandial state, with absorption 
increasing by up to three-fold when it is taken with 
food (especially high-fat meals). Debutyldronedarone, 
formed primarily by CYP3A4, is a major circulating 
metabolite with similar or even higher plasma exposure than 
  dronedarone.48   Debutyldronedarone has been demonstrated 
to be pharmacodynamically active but exhibits a potency 
that is 10%–33% that of the parent drug. The majority 
of the absorbed dronedarone is eliminated via first-pass 
metabolism, with only 15% bioavailability.49 Steady-state 
plasma concentrations of 84–167 ng/mL are reached in 
1 week by administration of dronedarone 400 mg twice 
daily.50 The primary metabolic clearance of dronedarone is 
driven by hepatic CYP3A4-dependent mechanisms, with a 
terminal half-life of   approximately 24 hours.51
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Dronedarone also interacts with commonly prescribed 
drugs, such as metoprolol and simvastatin.52 For example, 
dronedarone can increase serum simvastatin levels by 
2–4-fold, and promote statin-induced myopathy. The 
interaction between dronedarone and metoprolol depends 
on CYP2D6 inhibition and results in increased bioavail-
ability of metoprolol. Dronedarone also has interactions 
with other drugs using the CYP system, so should not be 
administered with potent CYP3A4 inhibitors, including 
antifungals, certain oral macrolide antibiotics, and protease 
inhibitors, because CYP3A4 inhibition may increase plasma 
levels of dronedarone and cause unwanted adverse effects. 
  However, dronedarone can be coadministered with moderate 
CYP3A4 inhibitors, such as verapamil and diltiazem, but 
with some caution, eg, by using lower drug doses.
Although dronedarone has no effect on glomerular filtra-
tion rate, slightly increased creatinine levels are reported in 
patients treated with dronedarone. These can be explained by 
partial inhibition of tubular transport of creatinine.53 Some 
of the available data concerning the molecular and electro-
physiological mechanisms of action and preclinical efficacy 
of dronedarone are discussed below.
Dronedarone was approved by the US Food and Drug 
Administration in March 2009 to reduce the risk of cardiovas-
cular hospitalization in patients with paroxysmal or persistent 
atrial fibrillation or atrial flutter. Approval was justified due 
to the positive results of the ATHENA trial showing sig-
nificant reductions in all-cause mortality and cardiovascular 
hospitalization with the use of dronedarone.47 Dronedarone 
was developed to accommodate the need for a potent anti-
arrhythmic drug without the side effects of amiodarone. Its 
electrophysiological properties are similar to amiodarone, 
but there are several structural differences.54
Dronedarone is primarily a class III antiarrhythmic drug 
but it has properties from all four classes according to the 
Vaughan–Williams classification of antiarrhythmic drugs. It 
also has antiadrenergic properties and inhibits multiple trans-
membrane potassium currents, including the delayed rectifier 
current (both the rapid and slow components [IKr and IKs, 
respectively]), the ultrarapid delayed rectifier current (IKur), 
the inward rectifier current (IK1), the transient outward 
current (ITo), and the sodium and L-type calcium currents. 
Dronedarone has a methylsulfonamide group, making it less 
lipophilic than amiodarone and thus having a much shorter 
half-life, with reduced tissue accumulation.55 The European 
Medicines Agency Committee for Medicinal Products for 
Human Use has approved dronedarone for use in clinically 
stable adult patients with a history of or   current nonpermanent 
atrial fibrillation, to prevent recurrence of atrial fibrillation, or 
to lower the ventricular rate.56 The available data show that 
no dose reductions are required for dronedarone.
In rabbit and guinea pig heart models, both amiodarone 
and dronedarone prolong the ventricular and atrial refrac-
tory periods, suppress the automaticity of the sinoatrial node 
due to prolongation of the action potential, and decrease 
the maximum slope of the action potential upstroke, which 
reflects blocking of the fast sodium channel activity of the 
myocardium. Dronedarone slows the sinus rate and causes 
a dose-dependent lengthening of the corrected QT interval, 
and, with escalating doses, causes prolongation of the PR 
interval. In spite of these similarities, the antagonistic effects 
of the two drugs are not equivalent. In vitro data show that 
dronedarone has a stronger inhibitory effect on the peak 
sodium current and on the acetylcholine-activated potassium 
current than amiodarone.57
Clinical trials with dronedarone
All clinical studies with dronedarone have been multina-
tional, multicenter, double-blind, placebo-controlled, and 
of parallel design with comparable demographics, except 
for the DIONYSOS (Efficacy and safety of dronedarone 
versus amiodarone for the maintenance of sinus rhythm 
in patients with atrial fibrillation) trial which was actively 
controlled.58 There have been seven trials undertaken which 
were designed to help establish the efficacy, dosage, and 
rate control achieved with dronedarone. These clinical tri-
als are categorized by their primary intention, ie, according 
to whether they are studies of rhythm control, rate control, 
mortality/morbidity, or comparative efficacy.
Initial dose-ranging trial
DAFNE (the Dronedarone Atrial FibrillatioN study after 
Electrical cardioversion) was a prospective, double-blind, 
randomized, placebo-controlled Phase II study performed 
in patients with persistent atrial fibrillation, in whom car-
dioversion and drug therapy were warranted. The study 
was designed to establish the optimal therapeutic dose of 
dronedarone for rhythm control of atrial fibrillation. A total 
of 270 patients, aged 21–85 years, with persistent atrial 
fibrillation, were randomized to three different doses of 
dronedarone (400 mg, 600 mg, or 800 mg twice daily) or 
placebo, and were then followed for 6 months. Patients with 
unstable angina, recent myocardial infarction, New York 
Heart Association (NYHA) class III–IV congestive heart 
failure or left ventricular ejection fraction less than 35% were 
excluded. If they failed to convert to sinus rhythm within 
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5–7 days of starting dronedarone therapy, the patients were 
electrically cardioverted. The primary endpoint was the time 
to first recurrence of atrial fibrillation during the 6 months 
of follow-up. Secondary endpoints included spontaneous 
conversion of atrial fibrillation, heart rate in atrial fibrillation, 
and occurrence of adverse events.
Dronedarone 400 mg twice daily was found to prolong 
the period to first recurrence of the arrhythmia significantly, 
and was better tolerated with fewer side effects. In DAFNE, 
dronedarone was not associated with thyroid, pulmonary, 
neurological, ocular, or pulmonary toxicity. Dronedarone 
treatment led to dose-dependent prolongation of the QT 
interval, but no cases of torsades de pointes were reported. 
Patients treated with the highest doses had more gastrointes-
tinal toxicity leading to drug discontinuation. After 6 months, 
the percentage of patients on dronedarone 400 mg twice daily 
and back in atrial fibrillation was 65% vs 90% for those on 
placebo. The median time to reversion back to atrial fibril-
lation was 60 days vs 5 days for placebo (P = 0.001). In 
summary, the DAFNE study demonstrated the safety and 
moderate efficacy of dronedarone 400 mg twice daily for the 
management of persistent atrial fibrillation.59 Limitations of 
DAFNE included the investigators’ inability to explain fully 
the lack of a dose-related response to dronedarone and the 
relatively high recurrence rate of atrial fibrillation.
Rate control of atrial fibrillation
Dronedarone has also been studied as a rate-controlling agent 
for atrial fibrillation. The ERATO trial (Efficacy and safety 
of dRonedArone for The control of ventricular rate during 
atrial fibrillation) enrolled 174 subjects (older than 21 years, 
predominantly elderly males .65 years) with permanent 
atrial fibrillation of more than 6 months’ duration and had a 
6-month follow-up period. The patients were randomized to 
receive 800 mg of dronedarone daily or placebo.27
At the time of first recurrence of atrial fibrillation, 
dronedarone appeared to slow the ventricular response in 
a dose-dependent fashion. Patients receiving dronedarone 
800, 1200, or 1600 mg had their ventricular rate reduced 
by 13.2, 19.2, and 17.8 beats per minute on average, 
respectively, compared with those on placebo (P = 0.0001). 
The results after 4 months of follow-up showed that the 
rate-controlling effect of dronedarone was sustained over 
time. The efficacy of dronedarone therapy also appeared 
to be additive to the effects of conventional background 
rate-controlling therapy, including calcium antagonists, 
beta-blockers, and digoxin. There were no untoward inter-
actions between dronedarone and other rate-controlling 
agents or anticoagulants, except for a 41% increase in 
serum digoxin concentrations.
In conclusion, dronedarone is an effective rate controlling 
agent, both at rest and during exercise, without negative 
effects on exercise tolerance. In patients who suffer 
recurrence of atrial fibrillation, dronedarone may decrease 
symptoms and consequently lower hospital admissions and 
emergency room visits.
Maintaining normal sinus rhythm
EURIDIS (the EURopean trial In atrial fibrillation or flutter 
patients receiving Dronedarone for the maintenance of Sinus 
rhythm) and ADONIS (the American-Australian-African 
trial with DrOnedaroNe in atrial fibrillation or flutter patients 
for the maintenance of Sinus rhythm) were sister trials that 
evaluated dronedarone for the maintenance of sinus rhythm 
in 828 patients who received dronedarone and 409 patients 
who received placebo, each patient group aged over 21 years, 
with a follow-up duration of 12 months.60 Time to recur-
rence of atrial fibrillation, which was the primary endpoint 
of the trial, was significantly longer in patients treated with 
dronedarone. Furthermore, heart rate at first recurrence of 
atrial fibrillation was lowered significantly with dronedarone. 
A post hoc analysis revealed a 27% reduction of relative risk 
of hospitalization and death with dronedarone treatment. The 
rates of cardiac and extracardiac adverse events in these trials 
were comparable with those of the placebo arm. There was 
a reported incidence of serum creatinine elevation of 2.4% 
in patients in the dronedarone group.
Effect on morbidity/mortality
The AFFIRM trial, which included 4060 patients, showed 
that rhythm control strategies do not translate into a survival 
benefit. AFFIRM found no significant difference in mortal-
ity or stroke risk between the treatment strategies of rate or 
rhythm control.61 A post hoc analysis of the AFFIRM data 
revealed that although maintenance of sinus rhythm was 
associated with better survival, this benefit was neutralized 
by increased mortality from antiarrhythmic drug use.10
The ATHENA study evaluated 4628 high-risk patients 
with paroxysmal or persistent atrial fibrillation/atrial flutter. 
High risk was defined as patients older than 75 years with at 
least one of the following: hypertension, diabetes, prior cere-
brovascular accident or systemic embolism, left ventricular 
ejection fraction ,40% or left atrial diameter .50 mm.58,62 
Patient characteristics and drug treatment were similar in 
both arms, although it must be noted that the ATHENA trial 
was not designed as a head-to-head comparison between 
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dronedarone and amiodarone. The primary endpoint was 
defined as first hospitalization for cardiovascular reasons or 
mortality from any cause.
Thirty-two percent of patients in the dronedarone arm 
and 39% in the placebo arm reached the primary endpoint. 
  Dronedarone reduced the first cardiovascular hospitalization 
by 26% when compared with placebo (P , 0.001). The reduc-
tion in need for repeated hospitalization for cardiovascular 
events was due to fewer hospital admissions for treatment 
of atrial fibrillation or acute coronary syndromes. All-cause 
mortality was similar in both study arms. Discontinuation 
of the study drug was similar in both groups, indicating 
good tolerability. Dronedarone proved to be effective and 
safe in reducing cardiovascular outcomes (cardiovascular 
hospitalization or death) in patients with atrial fibrillation 
or flutter. A post hoc analysis of the AFFIRM data revealed 
that although maintenance of sinus rhythm was associated 
with better survival, this benefit was neutralized by increased 
mortality from antiarrhythmic drug use.10 Baseline risk fac-
tors for stroke were well balanced between the two groups, 
and the percentage of patients receiving oral anticoagulants 
with therapeutic INR was also similar. The baseline risk 
of stroke was assessed using the CHADS2 score, which 
is calculated by assigning one point each for the presence 
of congestive heart failure, hypertension, age 75 years or 
older, and diabetes mellitus, and two points for history of 
stroke or transient ischemic attack.62 Patients included in 
the study had an intermediate to high risk for stroke and 
other cardiovascular events, with a mean CHADS2 score of 
2 in both groups. Patients with a CHADS2 score $2 had a 
significantly greater effect of dronedarone than those with a 
CHADS2 score # 1 (P = 0.03 for interaction). Dronedarone 
reduced the risk of stroke by 34% from 1.8% per year to 1.2% 
per year (hazards ratio [HR]: 0.66, P = 0.027). Consequently, 
this analysis showed a reduction of stroke with dronedarone 
in high-risk patients.62
Patients with heart failure
The ANDROMEDA trial (ANti-arrhythmic trial with 
DROnedarone in Moderate-to-severe congestive heart failure 
Evaluating morbidity DecreAse) was designed to evaluate the 
effect of dronedarone on morbidity in patients with unstable 
NYHA class II–IV heart failure, regardless of their arrhyth-
mia history.63 After inclusion of 627 patients (310 in an 
800 mg daily dronedarone group and 317 in a placebo group), 
the trial was prematurely terminated for safety reasons, at 
the recommendation of the Data and Safety Monitoring 
Board, in accordance with the board’s predefined rules for 
study   termination. During a median follow-up of 2 months, 
25 patients in the dronedarone group (8.1%) and 12 patients 
in the placebo group (3.8%) died (HR in the dronedarone 
group 2.13; 95% confidence interval [CI]: 1.07–4.25; 
P = 0.03). The excess mortality was predominantly related to 
worsening of heart failure, with 10 deaths in the dronedarone 
group and two in the placebo group. The primary endpoint did 
not differ significantly between the two groups; there were 
53 (17.1%) events in the dronedarone group and 40 (12.6%) 
events in the placebo group (HR: 1.38; 95% CI: 0.92–2.09; 
P = 0.12). More increases in creatinine levels were reported 
as serious adverse events in the dronedarone group than in 
the placebo group. The risk of death and hospitalization 
was higher in patients with the most severe left ventricular 
systolic dysfunction. The study was stopped prematurely due 
to increased mortality in the dronedarone group, primarily 
due to worsening heart failure. There is now a black box 
warning in the package insert against the use of this drug in 
patients with NYHA class IV heart failure or class II–III heart 
failure with recent decompensation requiring hospitalization 
or referral to a heart failure specialist. As a direct result of 
the ANDROMEDA trial, dronedarone is contraindicated 
in patients with NYHA class III and IV or in patients with 
recent exacerbation of heart failure.
The ATHENA trial included patients with NYHA class II–
III heart failure and a left ventricular ejection fraction ,40% 
at baseline (114 on placebo and 95 on dronedarone). Unlike 
prior studies, this trial had a composite primary endpoint 
of all-cause mortality and cardiovascular   hospitalization.64 
A primary outcome event occurred in 59/114 placebo patients 
compared with 42/95 patients receiving dronedarone. Twenty 
of 114 placebo patients and twelve of 95 dronedarone patients 
died during the study. Fifty-four placebo patients and 42 
dronedarone patients were hospitalized for an intermittent 
episode of NYHA class IV heart failure. There was a trend 
toward lower overall mortality with dronedarone treatment, 
and, importantly, there was a statistically significant reduc-
tion in death due to cardiac arrhythmia. A post hoc analysis 
demonstrated that dronedarone was associated with a signifi-
cant reduction in the adjusted risk of stroke compared with 
placebo.62 This benefit was preserved in patients who were 
already receiving antithrombotic therapy.65 Due to the risk 
of torsades de pointes associated with sotalol and dofetilide, 
physicians have typically waited 1 month or more to start-
ing these drugs after stopping amiodarone. In the ATHENA 
trial, patients had to stop amiodarone at least 1 month prior 
to enrollment in the trial. The earlier EURIDIS and ADONIS 
trials allowed patients to be enrolled immediately after 
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  discontinuation of amiodarone. Physicians are currently using 
their clinical judgment in deciding on this question, but no 
one is advocating this switch in patients whose arrhythmia 
is well controlled if they are not experiencing any adverse 
effects on amiodarone.
Dronedarone versus amiodarone
When initial results were discussed with the European 
Agency for the Evaluation of Medicinal Products, it was 
requested that a comparison be made with amiodarone. This 
was done using DIONYSOS, a multicenter, randomized, 
double-blind, parallel-arm study comparing dronedarone 
400 mg twice daily with amiodarone 600 mg daily for 
28 days and 200 mg daily thereafter, for the maintenance 
of sinus rhythm in patients with atrial fibrillation. In total, 
504 patients of mean age 64.0 ± 10.7 years were randomly 
allocated to dronedarone (n = 249) or amiodarone (n = 255), 
and electrical cardioversion was performed if necessary. 
Patients could be included if they had documented atrial 
fibrillation for more than 72 hours and required cardiover-
sion and antiarrhythmic therapy. Patients with NYHA class 
III–IV congestive heart failure were excluded. The primary 
endpoint was a composite time to first recurrence of atrial 
fibrillation or premature discontinuation of the study drug 
because of intolerance or lack of efficacy.
At a mean follow-up of 7 months, fewer amiodarone-
treated patients reached the primary endpoint compared with 
those treated with dronedarone (55.3% vs 73.9%, P , 0.001), 
indicating that amiodarone showed more sustained efficacy 
than dronedarone. Patients on amiodarone tended to experi-
ence more premature drug discontinuation (34 vs 26) than 
patients on dronedarone. At 12 months, more patients given 
dronedarone had recurrence of atrial fibrillation or prema-
turely stopped taking the study drug (75.1% vs 58.8%, HR: 
1.589, 95% CI: 1.275–1.980; log rank P value ,0.0001). 
Amiodarone was found to be more effective than dronedarone 
in maintaining sinus rhythm.
The main safety endpoint in DIONYSOS was time to first 
occurrence of thyroid, hepatic, pulmonary, neurological, skin, 
ocular, or specific gastrointestinal events, or premature dis-
continuation of the study drug because of any adverse effects. 
This happened in 39.3% of patients taking dronedarone and 
44.5% of those taking amiodarone after 12 months (HR: 
0.80, CI: 0.60–1.07; log rank P value = 0.13). Patients treated 
with dronedarone had a significantly higher prevalence of 
adverse gastrointestinal events and a significantly lower 
incidence of thyroid (two vs 15) and adverse neurological 
events (three vs 17).
Intolerance of dronedarone was mainly secondary 
to gastrointestinal side effects (diarrhea, vomiting, and 
nausea), and was responsible for discontinuation of the 
drug in only 3.2% of patients in clinical trials, while thyroid 
and neurological events (tremor and sleep disorder) were 
mostly responsible for discontinuation of amiodarone.66 
Fewer patients in the dronedarone group had a QTc interval 
.500 milliseconds (10.9% vs 20.5%, respectively). No cases 
of torsades de points were reported in either study arm. The 
incidence of recurrence of atrial fibrillation in the dronedarone 
arm was higher than in the amiodarone arm, whereas adverse 
events leading to premature drug discontinuation tended to 
be less frequent in the dronedarone arm. These factors, along 
with fewer hospitalizations and decreased stroke risk seen in 
the ATHENA trial, may result in a decreased cost of treatment 
in dronedarone patients. However, no cost-efficacy analyses 
have been done to confirm this theory.
The superiority of amiodarone in preventing recurrence of 
atrial fibrillation is consistent with an indirect meta-analysis 
based on placebo-controlled trials of amiodarone and placebo-
controlled trials of dronedarone.67 They included direct ran-
domized data obtained from the DIONYSOS trial, together 
with other controlled studies that randomized patients with 
atrial fibrillation to amiodarone, dronedarone, or placebo.67 
The results of this comparison showed that treatment with 
amiodarone was associated with a greater likelihood of 
remaining in sinus rhythm (odds ratio [OR]: for recurrent 
atrial fibrillation 0.49, 95% CI: 0.37–0.63; P , 0.001) in 
comparison with dronedarone. On the other hand, the authors 
also observed a trend toward greater all-cause mortality (OR: 
1.61, 95% CI: 0.97–2.68; P = 0.066) and a greater number 
of adverse events requiring drug discontinuation with amio-
darone versus dronedarone (OR: 1.81, 95% CI: 1.33–2.46; 
P , 0.001).67 In conclusion, DIONYSOS clearly confirms that 
dronedarone is less effective than amiodarone in maintaining 
sinus rhythm and in preventing recurrence of atrial fibrillation 
in patients with a history of atrial fibrillation. Dronedarone 
can be considered as an alternative therapy to amiodarone and 
tried prior to amiodarone, especially in younger patients.
Safety of dronedarone
Because CAST (the Cardiac Arrhythmia Suppression Trial) 
showed that antiarrhythmic therapy with class IC drugs 
increases mortality in patients after myocardial infarction, 
there has been a justified focus on the safety of antiarrhyth-
mic drugs. Currently, amiodarone is the only antiarrhyth-
mic drug that is used in high-risk patients, even though it 
is not approved for this indication by the Food and Drug 
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  Administration. It often causes prolongation of the QT inter-
val and in some cases torsades de pointes. The extracardiac 
safety problems reported with amiodarone, in particular 
thyroid, eye, skin, nervous system, liver, respiratory, thoracic, 
and mediastinal disorders, were reported in comparable fre-
quencies with dronedarone and placebo. This argues in favor 
of a better extracardiac safety profile for dronedarone than 
amiodarone. The DIONYSOS study showed that premature 
study drug discontinuation following an adverse event tended 
to occur less frequently in the dronedarone group than in the 
amiodarone group. Dronedarone prolongs the QT interval, 
but the risk of torsades de pointes is low. The DYONISOS 
trial did not report any cases of torsades de pointes, and only 
one case was reported in the ATHENA trial.
Dronedarone should not be used in conjunction with other 
drugs that prolong the QT interval. While periodic electrocar-
diograms are recommended to monitor patients for a prolonged 
QT interval and bradycardia, no chest X-rays or laboratory tests 
to monitor thyroid and hepatic function are required. Since 
there is no significant interaction with warfarin, more frequent 
monitoring of coagulation is not needed. Patients should take 
dronedarone with food to increase absorption, and should avoid 
grapefruit juice, which can increase serum levels of this drug. 
Dronedarone has not been studied in pregnant women. However, 
the drug has been found to be teratogenic in animal studies.
The DYONISOS study suggested a better safety profile 
for dronedarone, chiefly due to fewer thyroid, neurological, 
skin, and ocular events. The most common side effects of 
dronedarone are gastrointestinal, including diarrhea and 
nausea, which are more frequent than with amiodarone 
or with placebo (Table 1). Photosensitivity reactions and 
dysgeusia have also been reported, with an incidence of   
less than 1% in patients treated with dronedarone. Labo-
ratory data and electrocardiographic parameters reported 
with dronedarone tablets 400 mg twice daily are shown in 
Table 2.
Dronedarone increases serum creatinine by 10%–15%, 
but without adverse effects on glomerular filtration rate or 
renal plasma flow in patients and healthy individuals. This is 
due to partial inhibition of tubular organic cation transporters, 
and this is also seen during treatment with amiodarone.
With respect to vitamin K antagonists, drug interac-
tions were less frequent with dronedarone than with amio-
darone, with fewer hemorrhagic events. Notwithstanding, 
some drug interactions may be relevant. Plasma levels 
of dronedarone may be increased several-fold in patients 
taking a strong inhibitor of CYP3A4, like ketoconazole, 
itraconazole,   voriconazole, telithromycin, clarithromycin, 
ciclosporin, and ritonavir, and these drugs are contraindi-
cated in such   situations. On the other hand, during treat-
ment with dronedarone, potent CYP3A4 inducers, such 
as phenobarbital, carbamazepine, phenytoin, or St John’s 
wort, are not   recommended because they decrease drone-
darone exposure up to five-fold. Dronedarone 400 mg twice 
daily increased   simvastatin and simvastatin acid exposure 
2–4-fold,   respectively, and increased exposures of lovas-
tatin, atorvastatin, and pravastatin within the same range 
as simvastatin. Although interaction with some statins 
(CYP3A4 substrates) could hypothetically lead to increased 
risk of statin-related adverse events, especially myopathy, 
data from the   ATHENA trial and the integrated analyses did 
not confirm this assumption. Dronedarone may increase the 
plasma levels of some beta-blockers (metoprolol, propra-
nolol) and calcium channel blockers (verapamil, diltiazem), 
and dose adjustments of beta-blocker treatment may be 
needed after introduction of dronedarone. In the ERATO 
Table 2 Laboratory data and electrocardiographic parameters 
not necessarily reported as adverse events
Placebo Dronedarone  
400 mg twice daily
Serum creatinine increased $10%  
5 days after treatment initiation
(n = 2875)  
21%
(n = 3282)  
51%
QTc Bazett prolonged  
(.450 milliseconds in males  
and .470 milliseconds in females)
(n = 2237)  
19%
(n = 2701)  
28%
Data from Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. 
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 
2003;24(16):1481–1487.
Table 1 Adverse drug reactions more frequent than placebo
Placebo 
(n = 2875)
Dronedarone  
400 mg twice daily   
(n = 3282)
Gastrointestinal
  Diarrhea 6% 9%
  Nausea 3% 5%
  Abdominal pain 3% 4%
  vomiting 1% 2%
  Dyspeptic signs and symptoms 1% 2%
General
  Asthenic conditions 5% 7%
Cardiac
  Bradycardia 1% 3%
Skin and subcutaneous tissue
  Including rashes (generalized,  
  macular, maculopapular,  
  erythematous), pruritus, eczema,  
  dermatitis, dermatitis allergic
3% 5%
Data from Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. 
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 
2003;24(16):1481–1487.
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trial, the mean increase in digoxin levels in the dronedarone 
arm compared with   placebo was 41.4%, but the number of 
patients with digoxin levels outside the normal range in the 
two groups did not differ significantly.
Although no hepatic toxicity was detected during 
Phase III trials of dronedarone, post-marketing surveil-
lance has recently identified two cases of severe hepatic 
failure requiring transplantation amongst approximately 
180,000 patients exposed worldwide. No definite causal 
relationship between dronedarone and liver injury has been 
established, but close monitoring of liver function tests is 
recommended.
Conclusion
Dronedarone, like amiodarone, has effects on multiple cardiac 
ion channels and receptors. This agent can be considered as a 
first-line therapy for atrial fibrillation in patients with structural 
heart disease who have an ejection fraction .35% and no recent 
decompensated heart failure. Dronedarone has been proven to 
maintain sinus rhythm and to control the ventricular rate during 
episodes of atrial fibrillation in several clinical trials. In ATH-
ENA, dronedarone reduced cardiovascular hospitalizations 
and mortality in high-risk patients with atrial fibrillation.
Dronedarone has a well-described side-effect profile, the 
principal adverse effect being diarrhea, which may necessitate 
drug discontinuation. Dronedarone causes dose-dependent 
prolongation of the QTc interval, but torsades de pointes is 
rare. The drug increases serum creatinine by inhibition of 
tubular secretion. This effect is not associated with reduced 
renal function and is reversible, but needs to be considered, 
particularly in patients receiving other drugs like angiotensin-
converting enzyme inhibitors that also increase serum crea-
tinine. The safety of dronedarone in patients with advanced 
heart failure is a concern. Patients with severe systolic heart 
failure and hemodynamic instability should not receive 
dronedarone. Theoretically, dronedarone use should result in 
lower health care cost for atrial fibrillation patients due to its 
favorable safety profile, lowering of stroke risk, and reduc-
tion in cardiovascular hospitalizations. The ultimate role for 
dronedarone is yet to be defined. Little evidence exists as to 
whether it will succeed when other drugs have failed.
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